Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Optical coherence tomography in multiple sclerosis.
Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis.
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.
Significance of Virchow-Robin Spaces in Patients Newly Diagnosed with Multiple Sclerosis: A Case-Control Study in an Arab Population.
Analysis of the Paired TCR α- and β-chains of Single Human T Cells.
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.
Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge.
A touch of MS: Therapeutic mislabeling.
Using a highly abbreviated California Verbal Learning Test-II to detect verbal memory deficits.
[Sexuality of men with neurologic disorders].
Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS
Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury.
Segway use in individuals with multiple sclerosis.
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
Paroxysmal Hypothermia in Two Patients with Multiple Sclerosis.
Ongoing Oxidative Stress Causes Subclinical Neuronal Dysfunction in the Recovery Phase of EAE.
[Inflammatory brain pseudotumor. A variant of demyelinating disease that simulates high-grade glioma].
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine.
MARINOL®
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes.
The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab.
The next generation of exoskeletons: lighter, cheaper devices are in the works.

Pages